PSA production may be lower in African-American than Caucasian men with low-risk prostate cancer (PCa), a new study suggests. If confirmed, the finding could impact active surveillance criteria for black patients. Read the article.
Black Men with Low-Risk Prostate Cancer Produce Less PSA Read More »
High-intensity focused ultrasound (HIFU) is a treatment option for low- and intermediate-risk prostate cancer and more recently has been used as salvage therapy after failed radiation therapy. The article presents a case of local recurrence with biochemical failure after radical prostatectomy and salvage external beam radiation therapy with salvage HIFU without biochemical recurrence at 20 months. Read the article.
Doctors at Toronto’s Sunnybrook Hospital are exploring a new, more precise way of administering radiation therapy to patients with prostate cancer. Stereotactic ablative body radiotherapy, or SABR, allows doctors to give patients a high dose of radiation in a short period of time, replacing the long hours of treatment commonly associated with radiation therapy. “What’s really revolutionary about this is that patients used to have to come for up to eight weeks of radiotherapy — one treatment per day, five days a week,” said Sunnybrook oncologist Andrew Loblaw. “Now with this new trial, we’ve been able to show that you
Toronto hospital tests new, high-precision method of prostate cancer treatment Read More »
Hamilton researchers are attempting to create a prostate cancer vaccine that would use viruses to destroy cancer cells and trigger an immune response. Funded primarily by a $5-million grant from popular fundraiser Movember and Prostate Cancer Canada, the vaccine will be manufactured in Hamilton and Ottawa and tested on patients who currently have no other course of treatment. Read the article.
McMaster gets $5M to test prostate cancer vaccine Read More »
The US Food and Drug Administration has approved SonaCare Medical’s Sonablate 450 focused ultrasound system for the ablation of prostate tissue. Focused ultrasound enables treatment of organ-confined prostate disease while preserving surrounding healthy tissue, without radiation or surgery. Read the article.
FDA Approves First Focused Ultrasound System for Treating the Prostate Read More »
A GEL that prevents damage from radiotherapy could help thousands of men treated for prostate cancer by separating the prostate gland from the rectum. Read the article.
Wonder gel protects prostate patients from collateral damage Read More »
For patients who experience a recurrence, traditional treatment options have been historically limited to either radiation or hormonal therapy. Mayo Clinic urologists, however, offer patients advanced clinical options, including novel treatments specifically for recurrent prostate cancer. Read the article.
Novel Treatments For Recurrent Prostate Cancer Read More »
Men receiving active surveillance were 24 times more likely to die from causes other than prostate cancer over 15 years. Caucasian men with favorable-risk prostate cancer who opt for active surveillance have a low risk of progression to lethal cancer for a decade after diagnosis, according to researchers. Read the article.
Prostate Cancer Deaths Rare Among Low-Risk Patients on Active Surveillance Read More »
Chemotherapy at the start of hormone therapy can extend the lives of men with prostate cancer that has spread beyond the gland, a new study finds. Over nearly 29 months of follow-up, men with advanced prostate cancer who received the combination therapy lived almost 14 months longer than men who received only hormone therapy (58 months versus 44 months), researchers said. Read the article.
Adding chemotherapy to hormone therapy added 14 months to patients’ lives in study Read More »
Men with low-risk prostate cancer on active surveillance whose tumors are upgraded after a biopsy might not have to rush into surgery, according to new research. The men in this study had localized low-risk prostate cancer — a Gleason score of 3 + 3 or lower and a clinical stage of T1 or T2. All had a tumor upgrade while being managed with active surveillance The majority of the men who chose to remain on active surveillance after a tumor upgrade, rather than undergo immediate treatment, had no further progression of tumor grade. Read the article.
Active Surveillance May Be Safe After Prostate Tumor Upgrade Read More »